The market for Digital Oncology Therapeutics was estimated to be worth USD 1.72 billion in 2024, and it is projected to reach USD 3.17 billion by the end of 2030, growing at a CAGR of 9.15% over the forecast period.
Increased patient assistance programmes (PAPs), increased government activities for cancer awareness, rising cancer prevalence worldwide, strong R&D initiatives from key companies, and expanding demand for personalised medication are all factors driving market expansion.
Market Overview
Oncology therapeutics is the area of medicine which helps in identifying changes in cancer cells that stop or delay the growth of tumours that cause cancer in the patient's body. There are a variety of cancer treatments and therapy options available, depending on the stage and kind of cancer. Cancer treatments in clinical trials and research include targeted therapy, immunotherapy, hormone therapy, and stem cell transplant. During the projected period, the oncology treatments market is likely to benefit from rising cancer prevalence worldwide, increased cancer research, and increased government initiatives to raise cancer awareness.
According to the Globocan 2020 information sheet, there were an expected 19,292,789 new cancer cases identified globally, with about 9,958,133 cancer-related deaths. Furthermore, the International Agency for Research on Cancer (IARC) predicts that by 2040, the global burden of cancer would have increased to 27.5 million new cancer cases and 16.3 million deaths. The rising number of cancer cases is predicted to increase the demand for sophisticated cancer medicines and diagnostics to treat patients effectively along with the rise of digital technologies As a result of the aforementioned factors, the Digital Oncology Therapeutics market is predicted to rise rapidly over the forecast period.
The COVID-19 pandemic has had a huge influence on worldwide healthcare systems, as well as the market for Digital Oncology Therapeutics. Doctors from Cancer Institutes discovered that during the COVID-19 pandemic, there was a 46% decline in diagnoses of the six most frequent cancer types - breast, colorectal, lung, pancreatic, gastric, and oesophagal cancers, according to a paper published in Cancer Connect 2020. In addition, the Centers for Disease Control and Prevention (CDC) and many medical professional organisations recommended that cancer screening and other health-prevention services, as well as elective surgeries, be postponed unless the risks outweighed the benefits and that hospital infrastructure for COVID-19 patients is secured. As a result, the COVID-19 pandemic greatly influenced the market for Digital Oncology Therapeutics. The situation, though, is likely to progressively improve once the economy opens up and is restored.
MARKET DRIVERS
The industry is growing because of an increase in demand for personalised medicine.
Cancer is a devastating disease that claims the lives of hundreds of thousands of people each year. Standard treatments for disease heterogeneity, such as chemotherapy or radiation, are only effective in a small percentage of patients. Tumours can have a variety of origins and may express different proteins in one case vs another. This inherent heterogeneity in cancer lends itself to a developing field of perfection and well-supported medication development (PPM). PPM data is being collected in a variety of ways to describe molecular variations between tumours. Previously, several PPM products were available to link these variances to a useful medicine. PPM cancer treatments can provide enormous benefits to patients. Therefore, with the rise of technological advancements in the sector, PPM cancer treatments are becoming more popular augmenting the global market growth.
The digital oncology therapeutics market is growing due to increased global internet penetration.
The expansion in R&D and the increased occurrence of various types of malignancies are two main factors driving the market's growth. Furthermore, targeted therapy is gaining popularity due to its ability to target cancer cells while sparing non-target cells from the toxin. Bone cancer is the most common cancer in the region, and rising occurrences of the disease, as well as efficient treatment of bone cancer cases with targeted therapy, are driving market expansion. As a result of increased regulatory approvals and an increase in the prevalence of all types of cancer, the market is estimated to grow rapidly over the forecast period.
MARKET RESTRAINTS
Patients' reluctance to use digital therapies is limiting market expansion.
Digital therapeutics suppliers face a huge issue in motivating individuals to utilise digital treatments and gain their trust. While older and underprivileged people have the highest disease susceptibility and occurrence rates, they are the least likely to employ digital treatments due to a lack of technological knowledge. Furthermore, the maximum amount of behavioural change that can be detected using digital treatments is currently unknown.
Digital treatments are clinically validated and used on self-selected or volunteer patients, but their impact on patients with resistance is still unknown. Furthermore, there is limited evidence on total patient retention and long-term outcomes for digital treatments. Many patients still rely on traditional diagnostic and treatment methods and are hesitant to try new treatments. This is a significant threat to the digital therapies sector.
DIGITAL ONCOLOGY THERAPEUTICS MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
9.15% |
|
Segments Covered |
By Product Type, Technology, Application, End User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Johnson & Johnson |
Digital Oncology Therapeutics Segmentation:
The digital diagnostics and monitoring tools segment is anticipated to hold the highest market in 2022. This can be attributed to the increasing cases of cancer augmenting the need for the diagnoses and monitoring process to carry on the treatment procedures. The digital therapeutics segment is anticipated to be the fastest-growing segment due to the growing penetration of smartphone technologies and the cost-effective and efficient performance of digital technologies for healthcare providers and patients.
The Artificial Intelligence (AI) and Machine Learning (ML) technology segment dominated the market and accounted for the highest market share in 2022 with a share of around 35.8%. Chemotherapy, the most commonly used cancer treatment procedure when integrated with AI technologies aids healthcare professionals in developing a tailored digital profile of patients, allowing their dose to be customized during treatment. Increased research activities for integrating AI into chemotherapy are majorly accelerating segment growth.
The mobile health and wearables segment is anticipated to be the fastest-growing segment by technology due to the increased disposable income of people and the growing adoption of digital technologies and smart electronics among people.
The cancer screening and diagnosis segment accounted for the majority of the share of the total market revenue in 2022 and is anticipated to maintain its dominance during the forecasted years as well. This is due to the rising burden of cancer cases globally and the increasing launch of digital diagnostics platforms for cancer screening.
The patient and caregiver end-user segment accounted for the highest share of around 33.0% of the total market revenue in 2022. This growth can be majorly attributed to the increased adoption of digital therapeutic solutions by patients. With the growing number of patients diagnosed with cancer, the demand for digital therapeutics is increasing. On the other hand, the growth of the hospital and clinic end-user segment may be attributed to more healthcare providers implementing digital therapeutics to deliver & support oncology therapies that are clinically proven. The segment is anticipated to grow at the fastest CAGR during the forecast period
North America, Europe, Asia Pacific, South America, the Middle East and Africa make up the worldwide digital oncology therapeutics market. Because of the high prevalence of chronic diseases and government measures to assist technological innovation in digital therapeutics in the region, North America is estimated to be the largest market for digital therapeutics. The United States is likely to generate the most revenue in both the North American and global digital therapeutics markets. Furthermore, the US digital therapeutics market is likely to be driven by the refinement of pay structures for digital therapeutic solutions and accumulative investment in the field of digital therapeutics.
The Asia-Pacific region, on the other hand, is predicted to have immense potential for significant growth during the forecast period. The rising frequency of chronic illness, the region's growing senior population, and the rise of digital treatments are all contributing to the region's growth.
Digital Oncology Therapeutics by the company
The market for digital oncology therapeutics is fiercely competitive, with several significant firms. A few significant firms now dominate the market in terms of market share.
Strategic collaborations and increased investment in oncology research by significant firms help to secure their position and presence globally. GlaxoSmithKline PLC, for example, purchased TESARO Inc., an oncology-based biopharmaceutical business, in January 2020, expanding GSK's pipeline and commercial competence in cancer.
RECENT DEVELOPMENTS IN DIGITAL ONCOLOGY THERAPEUTICS
In March 2021, Pear Therapeutics (US) partnered with Spectrum Health Systems. (US). Pear Therapeutics has formed a relationship with Tufts Health Plan and Spectrum Health Systems to test FDA-approved digital therapeutics to help people with substance use disorders in their recovery journeys by providing solutions for greater treatment access and care innovation.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The market for Digital Oncology Therapeutics was estimated to be worth USD 1.72 billion in 2024, and it is projected to reach USD 3.17 billion by the end of 2030, growing at a CAGR of 9.15% over the forecast period.
The Global Digital Oncology Therapeutics Market is driven by the growing integration and adoption of digital technologies across different industry verticals globally.
The Segments under the Global Digital Oncology Therapeutics Market by Product Type are Digital Therapeutics (DTx), Digital Diagnostics and Monitoring Tools, Digital Decision Support Systems, and Tele-oncology Solutions.
China, Japan, South Korea, Singapore, and India are the most dominating countries in the Asia Pacific region for the Global Digital Oncology Therapeutics Market.
Amgen Inc., AstraZeneca plc, Bayer AG, and Bristol-Myers Squibb Company.are the three major leading players in the Global Digital Oncology Therapeutics Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
